Anne Wojcicki emphasized, "We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships." This highlights the company's shift towards a consumer and strategic partnership focus, abandoning its therapy development.
23andMe is currently under investigation by British and Canadian authorities due to a 2023 data breach that exposed personal details of 6.9 million users. The hackers had initially threatened to sell specific user data, raising significant privacy concerns.
As a consequence of the data breach, users have filed a class action lawsuit against 23andMe, alleging the company failed to provide adequate notification to affected users, especially those of Jewish and Chinese descent. Lawyers claim this negligence could create safety risks.
Facing mounting pressure, Wojcicki is attempting to take 23andMe private after the resignation of all but one board member, revealing internal dissent regarding the company’s strategic direction.
Collection
[
|
...
]